Curis shares rise as analysts see 'the next Pharmacyclics'

Shares of Curis rose premarket Friday as analysts see biotech company as potential take-out target

Related Keywords

United States ,American ,Robyn Karnauskas ,Abbvie Inc ,Curis Inc ,American Society Of Hematology ,Truist Securities ,American Society ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Cancer Drugs ,Healthcare Life Sciences ,Specialized Drugs Medications ,Analysts Amp 39 Comments Recommendations ,Ownership Changes ,Acquisitions Mergers Shareholdings ,Acquisitions Mergers ,Corporate Actions ,Corporate Industrial News ,Cancer ,Political General News ,Health ,Medical Conditions ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,C Amp Ampe Industry News Filter ,Scris ,Analysts Amp 39 Comments ,Recommendations ,Acquisitions ,Mergers ,Shareholdings ,Corporate ,Industrial News ,Political ,General News ,Healthcare ,Life Sciences ,Specialized Drugs ,Medications ,